Zhukovsky, Peter http://orcid.org/0000-0002-7181-2095
Tio, Earvin S. http://orcid.org/0000-0002-0521-779X
Coughlan, Gillian
Bennett, David A.
Wang, Yanling http://orcid.org/0000-0002-8589-4239
Hohman, Timothy J. http://orcid.org/0000-0002-3377-7014
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Mulsant, Benoit H. http://orcid.org/0000-0002-0303-6450
Voineskos, Aristotle N. http://orcid.org/0000-0003-0156-0395
Felsky, Daniel http://orcid.org/0000-0003-1831-9848
Article History
Received: 8 May 2023
Accepted: 4 June 2024
First Online: 18 June 2024
Competing interests
: Over the past 3 years, D.A.P. has received consulting fees from Albright Stonebridge Group, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sunovion, and Takeda; he has received honoraria from the Psychonomic Society and American Psychological Association (for editorial work) and from Alkermes; he has received research funding from the Brain and Behavior Research Foundation, the Dana Foundation, Millennium Pharmaceuticals, Wellcome Leap MCPsych, and NIMH; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. P.Z. was funded by the Canadian Institute of Health Research Postdoctoral Fellowship. G.C. was funded by the Alzheimer Society Canada Postdoctoral Fellowship. TH serves on the scientific advisory board for Vivid Genomics. D.F. is supported by the generous contributions from the Michael and Sonja Koerner Foundation and the Krembil Family Foundation. D.F. is also supported in part by the Centre for Addiction and Mental Health (CAMH) Discovery Fund and CIHR. B.H.M. holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received, within the past 5 years, research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study funded by the CAMH Foundation), and HAPPYneuron (software used in a study funded by Brain Canada). Within the past 5 years, B.H.M. has also received research support from Eli Lilly (medications for an NIH-funded clinical trial) and Pfizer (medications for an NIH-funded clinical trial). He has been an unpaid consultant to Myriad Neuroscience. A.N.V. currently receives funding from CIHR, the NIH, the National Sciences and Engineering Research Council (NSERC), the CAMH Foundation, and the University of Toronto. E.S.T. was funded by the Ontario Graduate Scholarship. The remaining authors declare no competing interests.